Javier Szwarcberg

Directeur Général chez SPRUCE BIOSCIENCES, INC.

Fortune : 55 592 $ au 30/06/2024

54 ans

Health Technology

Consumer Services

Postes actifs de Javier Szwarcberg

Sociétés	Poste	Début	Fin
SPRUCE BIOSCIENCES, INC.	Directeur/Membre du Conseil	03/01/2022	-
SPRUCE BIOSCIENCES, INC.	Directeur Général	03/01/2022	-

Sociétés	Poste	Début	Fin
BIOMARIN PHARMACEUTICAL INC.	Corporate Officer/Principal	01/02/2020	01/01/2022
ULTRAGENYX PHARMACEUTICAL INC.	Corporate Officer/Principal	01/10/2017	01/02/2020
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY	Directeur Technique/Scientifique/R&D	01/10/2016	01/10/2017

Universidad de Buenos Aires	Doctorate Degree
Harvard T.H. Chan School of Public Health	Graduate Degree

Internationale

Opérationnelle

Corporate Officer/Principal	2
Director/Board Member	1
Chief Executive Officer	1

Sectorielle

Health Technology	5
Consumer Services	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	3
SPRUCE BIOSCIENCES, INC.	Health Technology
BIOMARIN PHARMACEUTICAL INC.	Health Technology
ULTRAGENYX PHARMACEUTICAL INC.	Health Technology

Entreprise privées	1
Horizon Therapeutics Plc Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.	Health Technology

Entreprise privées

Health Technology